Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 1, 2003, Pages 1-7

  Hatsukami, Dorothy K ^a   Jensen, Joni ^a   Brauer, Lisa H ^a   Mooney, Marc ^a   Schulte, Susan ^a   Sofuoglu, Mehmet ^b   Pentel, Paul R ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

5HT3 antagonists; Cotinine; Nicotine patch; Nicotine withdrawal

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; COTININE; GRANISETRON; NEUROLEPTIC AGENT; NICOTINE; ONDANSETRON; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; SMOKING HABIT; TOBACCO; WITHDRAWAL SYNDROME;

NICOTIANA TABACUM;

EID: 0038635989     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00035-2     Document Type: Article

References (40)

1. Abood L., Reynolds D., Booth H., Bidlack J. Sites and mechanisms for nicotine's action in the brain. Neurosci. Biobehav. Rev. 5:1981;479-486.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed. 1994;Author, Washington, DC.
3. 3 receptor antagonists do not block nicotine induced hyperactivity in rats. Psychopharmacology. 119(2):1995;213-221.
4. 3 receptor ligands. Neurosci. Biobehav. Rev. 16:1992;107-113.
5. Chahine R., Calderone A., Navarro-Delmasure C. The in vitro effects of nicotine and cotinine on prostacyclin and thromboxane biosynthesis. Prostaglandins Leukot. Essent. Fatty Acids. 40:1990;261-266.
6. Chahine R., Aftimos G., Wainberg M.C., Navarro-Delmasure C., Abou Khalil K., Chahoud B. Cotinine modulates the cardiovascular effects of nicotine. Med. Sci. Res. 24:1996;21-23.
7. Corrigall W.A., Coen K. Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222. Pharmacol. Biochem. Behav. 49(1):1994;67-71.
8. 3 receptors. Pharmacol. Ther. 47(2):1990;181-202.
9. Crooks P.A., Dwoskin L.P. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. 54:1997;743-753.
10. Crooks P.A., Li M., Dwoskin L.P. Metabolites of nicotine in rat brain after peripheral nicotine administration, cotinine, nornicotine, and norcotinine. Drug Metab. Dispos. 25(1):1997;47-54.
11. DeClercq M., Truhaut R. Recherches sur le metabolisme du tryptophane chez le rat soumis a l'intoxication chronique par la cotinine. Etude de l'elmination urinaire et dosage dans le cerveau et les intestins de certains derives inoliques. Bull. Soc. Chim. Biol. (Paris). 45:1963;995-1001.
12. Dwoskin L., Teng L., Buxton S., Crooks P. (S)-(-)Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther. 288:1999;905-911.
13. Essman W.B. Nicotine-related neurochemical changes: some implications for motivational mechanisms and differences. Dunn W.L. Jr. Smoking behavior: motives and incentives. 1973;51-65 VH Winston and Sons, Washington, DC.
14. Faris P.L., Kim S.W., Meller W.H., Goodale R.L., Oakman S.A., Hofbauer R.D.et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet. 355:2000;792-797.
15. 3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs. 3:1992;79-85.
16. Fuxe K., Everett B.J., Hokfelt T. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol. Biochem. Behav. 10:1979;671-677.
17. Hatsukami D., Grillo M., Pentel P., Oncken C., Bliss R. Safety of cotinine in humans: physiologic, subjective and cognitive effects. Pharmacol. Biochem. Behav. 57:1997;643-650.
18. Hatsukami D., Lexau B., Nelson D., Pentel P., Sofuoglu M., Goldman A. Effects of cotinine on cigarette self-administration. Psychopharmacology. 138:1998;184-189.
19. Hatsukami D., Pentel P., Jensen J., Nelson D., Allen S., Goldman A.et al. Cotinine - effects with and without nicotine. Psychopharmacology. 135(2):1998;141-150.
20. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 86(9):1991;1119-1127.
21. Hughes J.R., Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry. 43:1986;289-294.
22. Hughes J.R., Hatsukami D. Errors in using tobacco withdrawal scale. Tob. Control. 7(1):1998;92-93.
23. Ishiguro H., Saito T., Akazawa S., Mitushio H., Tada K., Enomoto M.et al. Association between drinking-related antisocial behavior and a polymorphism in the serotonin transporter gene in a Japanese population. Alcohol. Clin. Exp. Res. 23(7):1999;1281-1284.
24. Johnson B., Roache J., Javors M., DiClemente C., Cloninger C., Prihoda T.et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 284(8):2000;963-971.
25. Keenan R.M., Hatsukami D.K., Pentel P.R., Thompson T., Grillo M.A. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin. Pharmacol. Ther. 55:1994;581-590.
26. Kim K.S., Borzelleca J.F., Bowman E.R., McKennis H. Effects of some nicotine metabolites and related compounds on isolated smooth muscle. J. Pharmacol. Exp. Ther. 161:1968;59-69.
27. Lerman C., Capaoraso N.E., Audrain J., Main D., Boyd N.R., Shields P.G. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol. Psychiatry. 5:2000;189-192.
28. Physicians' Desk Reference. Medical Economics, Montvale, NJ, 56th Edition: 2988-2989, 2002.
29. Riah O., Dousset J.C., Bofill-Cardona E., Courriere P. Isolation and microsequencing of a novel cotinine receptor. Cell. Mol. Neurobiol. 20(6):2000;653-664.
30. Roila F., Del Favero A. Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 29:1995;95-109.
31. Schuckit M., Mazzanti C., Smith T., Ahmed U., Radel M., Iwata N.et al. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol. Psychiatry. 45(5):1999;647-651.
32. Schuh L.M., Henningfield J.E., Pickworth W.B., Rothman R., Ohuoha D., Keenan R.M. Pharmacodynamic effects of cotinine. Perkins K.A., Benowitz N., Henningfield J., Newhouse P., Pomerleau O., Swan G. Proceedings of the 1st Annual Society for Research on Nicotine and Tobacco. Addiction. vol. 91:1996;143.
33. Sellers E.M., Toneatto T., Romach M.K., Somer G.R., Sobell G.R., Sobell M.B. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol. Clin. Exp. Res. 18:1994;879-885.
34. Simpson K.H., Murphy P., Colthup P.V., Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology. 109:1992;497-498.
35. Suzuki T., Ise Y., Mori T., Misawa M. Attentuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron. Life Sci. 61(16):1997;249-254.
36. Tiffany S.T., Drobes D.T. The development and initial validation of a questionnaire on smoking urges. Br. J. Addict. 86:1991;1467-1476.
37. Toth E., Sershen H., Hashim A., Vizi E.S., Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem. Res. 17:1992;265-271.
38. 3 antagonist. Eur. J. Cancer. 26(Suppl. 1):1990;S12-S15.
39. West R., Hajek P. Randomised controlled trial of ondansetron in smoking cessation. Psychopharmacology. 126(1):1996;95-96.
40. 3 antagonist, ondansetron, on cigarette smoking, smoke exposure, and mood in humans. Pharmacol. Biochem. Behav. 44:1993;387-391.